Latest News and Press Releases

Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase...

CNH accelerates product development and parts delivery with €21M investment in advanced simulation and automated logistics CNH invests €21M in advanced simulation and automated logistics in Modena,...

Incoming Chief Executive Officer Brings Two Decades of Defense Leadership, Most Recently at Israeli Loitering-Munitions Innovator SpearUAV, and Previously at Rafael Advanced Defense Systems, One of...

Destination reinforces the sportscar maker’s commitment to experiential brand engagement in Canada Brand celebrates the one-year anniversary of the opening of its first Canadian and tenth global...

Kennewick, WA, June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, is...

Liquidia (NASDAQ: LQDA) will present four posters, including ASCENT patient-reported cough outcomes, at the PHA 2026 International PH Conference in Dallas

LOS ANGELES, June 11, 2026 (GLOBE NEWSWIRE) -- via IBN -- Nightfood Holdings, Inc. (OTCQB: NGTF) ("Nightfood Holdings" or the "Company"), doing business as TechForce Robotics, today announced that...

PLAINVIEW, N.Y., June 11, 2026 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (NASDAQ: VECO), a global leader in compound semiconductor process equipment, today announced the first commercial acceptance...

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML – ...

-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient...